Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EGT 022

Next Previous
Drug Profile

EGT 022

Alternative Names: EG 22; EG-Decorin; EG-Mirotin; EGT022; HU-005

Latest Information Update: 28 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EyeGene
  • Developer EyeGene; Huons
  • Class Cardiovascular therapies; Eye disorder therapies; Membrane proteins; Peptides; Recombinant proteins; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Platelet-derived growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic foot ulcer; Diabetic retinopathy; Pressure ulcer
  • No development reported Retinopathy of prematurity

Most Recent Events

  • 28 Sep 2021 No development reported - Phase-II for Diabetic retinopathy in European Union (IM) (EyeGene pipeline, September 2021)
  • 28 Sep 2021 No development reported - Phase-II for Diabetic retinopathy in Hungary (SC) (EyeGene pipeline, September 2021)
  • 28 Sep 2021 Phase-II clinical trials in Diabetic foot ulcer in South Korea (Topical) (EyeGene pipeline, September 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top